
    
      An Open-Label, Multi-Centre, Randomized Parallel-Group Dose-Finding Study, Investigating
      Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients with Prostrate
      Cancer Requiring Androgen Ablation Therapy.
    
  